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SUMMARY 
Background 
Constipation is a common symptom with a significant health economic burden. Dyssynergic 
defaecation secondary to pelvic floor dysfunction is an under-recognised, potentially 
reversible cause of chronic constipation. Biofeedback therapy to reverse this is available 
predominantly in specialist centres for the management of chronic constipation.  
Aim 
To review the evidence pertaining to the pathophysiology of constipation and the importance 
of identifying and diagnosing pelvic floor dysfunction in this condition. To examine the 
efficacy of biofeedback in the management of patients with pelvic floor dysfunction.  
Methods 
Relevant articles addressing the pathogenesis of pelvic floor dysfunction and the use of 
biofeedback in constipation were identified from a search of Pubmed, MEDLINE Ovid and 
the Cochrane Library. Seventeen randomised controlled trials were included.   
Results 
Pelvic floor dysfunction refers to the paradoxical contraction of the pelvic floor muscles, anal 
sphincter or the generation of inadequate intra-abdominal pressure during attempts at 
defaecation.  Pelvic floor dysfunction is found in 13 – 74% of patient with constipation. 
Biofeedback is a treatment free of side-effects which can correct physiological abnormalities 
and improve symptoms and quality of life. Predictors of a beneficial response to biofeedback 
are hard stool consistency, short duration of laxative use and the presence of specific 
physiological parameters on anorectal manometry including a high anal straining pressure 
and prolonged balloon expulsion time.  
Conclusions 
Pelvic floor dyssynergia is a leading cause of chronic constipation and is potentially 
reversible. Biofeedback is the most successful available treatment for pelvic floor 
dyssynergia. Further studies of biofeedback employing standardised protocols and patient-
centred outcomes are required. 
 
  
Introduction 
Functional bowel disorders result in considerable morbidity and economic burden to 
individuals and the community.1 Greater than one third of new referrals to a luminal 
gastroenterology clinic are ultimately diagnosed with a functional bowel disorder.2 The direct 
and indirect economic burden of functional bowel disorders is likely to be significantly 
underestimated but is noted in the USA to be upwards of 20.2 billion dollars annually.3,4 
Patients diagnosed with functional bowel disorders report significantly decreased 
productivity and reduced mental and physical quality of life.5 The recently revised Rome IV 
Criteria are the standard utilised to diagnose and classify patients with a functional bowel 
disorder (Table 1).6,7  
 
Constipation is broadly defined as infrequent or difficult bowel emptying, specifically fewer 
than three bowel movements per week or straining during defaecation greater than 25% of 
the time.8 Constipation is a common condition affecting up to 20% of the population in the 
developed world, with a higher prevalence in women and the elderly.2,3,5 The 
pathophysiology of constipation is traditionally categorised into primary or secondary causes, 
the common causes of the latter are summarised in Table 2.9 In contrast, primary or 
functional constipation includes intrinsic disorders of the colon (i.e. slow transit constipation) 
and disordered defaecation characterised by structural (i.e. rectocele or enterocele) or 
functional (i.e. pelvic floor dysfunction, inadequate propulsion) abnormalities. The 
nomenclature used in defining constipation is confusing. To date, pelvic floor dysfunction 
has been referred to as: anismus,10,11 dyssynergic defaecation,10 functional defaecation 
disorder, rectal evacuatory dysfunction, “obstipation”, obstructive defaecation10,12 and 
paradoxical anal sphincter or puborectalis contraction13. Slow transit constipation is also 
known as colonic atony, colonic neuropathy and disordered motility.8,14 For the purposes of 
this review, the terms slow transit constipation, pelvic floor dysfunction and the more specific 
term, dyssynergic defaecation (see below), will be used.  
 
Historically, slow transit constipation has been considered the archetypal form of 
constipation. However, there have been significant recent insights regarding the 
pathophysiology of functional constipation, in part due to the development of new 
investigative techniques and better appreciation of the role that the pelvic floor plays in 
symptom generation. Functional constipation affects approximately 8% of patients attending 
a primary care practice in Australia.15 Functional subtypes of chronic constipation include: a) 
isolated functional defaecatory disorder (12%), b) isolated slow transit constipation (42%), c) 
a combination of slow transit constipation and defaecatory disorder (25%) and, d) 
constipation predominant irritable bowel syndrome (IBS) (20%) (characterised by abdominal 
pain and bloating with a normal colonic transit time).16 The Rome IV criteria further divides 
functional defaecatory disorders into those secondary to inadequate defaecatory propulsion 
and dyssynergic defaecation secondary to pelvic floor dysfunction.7 Overall the prevalence of 
pelvic floor dysfunction in patients reporting constipation ranges from 13 – 81%.1,17 The 
epidemiological inaccuracy is in large part relating to controversy regarding diagnostic 
definition and appropriate investigative techniques.  
The relationship between colonic transit and pelvic floor dysfunction also obscures the true 
prevalence of each condition. Klauser demonstrated that rectal filling caused by voluntary 
suppression of defaecation resulted in slowed transit through the right colon.18 In addition, 
patients with a combination of slow transit constipation and dyssynergic defaecation have 
been shown to have improvement in colonic transit post correction of evacuatory dysfunction 
suggesting, in many patients, that the colonic dysmotility may be a secondary process.19 
 
Normal defaecation is complex. It requires the coordination of increased intra-abdominal 
pressure in combination with concurrent pelvic floor muscle, anal sphincter relaxation and 
rectal sensation/perception.20 Dyssynergic defaecation occurs when there is paradoxical 
contraction or inadequate relaxation of the pelvic floor muscles during attempted defaecation. 
This impedes the passage of stool leading to incomplete or unsuccessful evacuation.11 
Dyssynergia is apparent in 50% of patients with chronic constipation who are refractory to 
standard medical management.21. Symptoms are not reliable predictors of underlying 
pathophysiology 22,23, so the possibility of dyssynergia should be considered in all patients 
with constipation. Classical symptoms of dyssynergia are excessive straining (84%), a 
sensation of incomplete evacuation (76%), passage of hard stools (65%), less than 3 bowel 
movements per week (62%)1 and digital manual manouvres such as disimpaction or vaginal 
splinting to relieve symptoms. When these symptoms are clustered in particular patients, the 
diagnosis should be especially carefully sought. Identifying patients with dyssynergia is 
important as effective and targeted interventions are available; successful treatment results in 
improvement in symptoms and quality of life with durable effects. 
  
Biofeedback using electromyography (EMG) intervention was first introduced in 1987 by 
Bleijenberg and Kuijpers as a treatment for dyssynergic defaecation.24 Since then, 
biofeedback therapy has demonstrated clinical efficacy in uncontrolled trials and a small 
number of randomised controlled trials (RCT).25 Biofeedback is based on ‘operant 
conditioning’ techniques and uses stimuli such as EMG sensors, balloons or manometry in 
order to learn to increase intraabdominal pressure effectively and coordinate relaxation of 
pelvic floor and anal sphincter musculature during defaecation.10,26  
 
This review summarises the current evidence regarding i) the pathophysiology of pelvic floor 
dysfunction in chronic constipation ii) diagnosis of pelvic floor dysfunction in chronic 
constipation iii) efficacy of managing dyssynergic defaecation with biofeedback therapy. Our 
aim is to synthesise and integrate the current evidence addressing the pathophysiology of 
pelvic floor dysfunction in constipation and the application of biofeedback in its 
management.  
 
Review Criteria and Methodology 
Online databases searched included Pub Med, MEDLINE Ovid and the Cochrane Central 
Trials Registry. All original research studies, reviews and systematic reviews published in 
English from January 1950 onwards were considered. The following key words were used 
alone or in combination; ‘constipation and levator ani,’ ‘constipation and pelvic floor 
muscle,’ ‘constipation and biofeedback,’ ‘dyssynergic defaecation pathophysiology,’ 
‘dyssynergic defaecation and biofeedback,’ ‘pelvic floor muscle and constipation review,’ 
‘anismus and biofeedback’, ‘obstructive defaecation and biofeedback’ and dyssynergia and 
biofeedback.’ Of the articles included, seventeen were randomised controlled trials. Articles 
were excluded if they incorporated paediatric patients, urinary or obstetric disorders, non- 
human studies, did not have an abstract available or one that was not published in English.  
 
 
Normal Defaecation 
 
Prior to examining disordered defaecation, the normal structures and processes involved in 
defaecation must be understood.  
The three muscular components that influence continence are the pelvic floor muscles 
(levator ani), internal anal sphincter (IAS) and external anal sphincter (EAS) (Figure 2).27 
The levator ani is a broad muscular dome comprising of 4 muscles: puborectalis, 
iliococcygeus, ischiococcygeus and pubococcygeus which have voluntary and reflexive 
functions.28 The latter function to provide physical support, acting as a dome shaped 
‘diaphragm,’ for the pelvic viscera.28 Whereas, the puborectalis is a U-shaped muscle which 
forms a sling around the upper anal canal and interdigitates its muscular fibres with the EAS 
(located caudally) before attaching anteriorly on the pubis.29 Puborectalis contraction acts as 
a sling by pulling the anorectal junction anteriorly forming the anorectal angle. This 
angulation of approximately 90 is maintained by tonic activity (postural reflex); creating a 
mechanical barrier which aids continence (Figure 2).20 The internal and external sphincters 
also form a physical barrier to defaecation by maintaining a higher anal pressure than rectal 
pressure.20 
If it is a socially acceptable time, an increase in rectal distension mediates the initiation of 
defaecation whereby a voluntary increase in intraabdominal pressure coupled with 
puborectalis relaxation widens the anorectal angle and straightens the passage of stool from 
the rectum to the anus, followed by external anal sphincter relaxation and stool evacuation 
(Figure 3). 22  If timing is not suitable for defaecation the EAS contracts voluntarily (via the 
pudendal nerve) and the rectum relaxes allowing further accumulation of stool.9,28 
 
Pathophysiology of Pelvic Floor Dysfunction in Chronic Constipation 
Dyssynergic defaecation is defined as the presence of functional constipation symptoms plus 
at least 2 of 3 physiological signs, the most common being paradoxical contraction of 
puborectalis (on anorectal manometry or surface electromyography) or a delayed balloon 
expulsion test time (Table 1).30 Dyssynergia occurs when there is paradoxical contraction, or 
failure to relax the pelvic floor muscles during defaecation. This augments the anorectal 
angle thereby causing a physical obstruction to defaecation (Figure 3).31 Evidence suggests 
there is a significant bi-directional brain-gut dysfunction in patients with dyssynergic 
defaecation when assessed by bidirectional cortical evoked potentials and transcranial 
magnetic stimulation.32 Inadequate propulsive force may also contribute to dyssynergic 
defaecation due to an insufficient increase in intrarectal pressure associated with the 
relaxation of the anal sphincter.31   
The aeitiology of dyssynergic defaecation is unclear and in 2/3rds of patients it is acquired in 
adulthood.10 A prospective survey of 100 patients by Rao demonstrated that dyssynergic 
defaecation began during childhood in 31%, after a physical event such as pregnancy, trauma 
or back injury in 29% and with no cause identified in 40% of patients.1,10  
 
Diagnosis and Management of Pelvic Floor Dysfunction in Patients with Chronic 
Constipation 
 
1. History and General Examination   
 
It is paramount on history taking to assess for symptoms of chronic obstructive constipation 
including incomplete evacuation and straining in addition to the usual stool pattern and 
consistency.33,34 Patients may also have multiple pelvic floor symptoms concomitantly 
including recurrent urinary tract infections, sexual dysfunction or prolapse which also 
indicate dyssynergia. In addition, patients with a history of sexual abuse have an increased 
prevalence of pelvic floor dyssynergia.35  
 As with all function disorders, a thorough history including detailed questioning regarding 
alarm symptoms must be undertaken. Alarm symptoms on history include: rectal bleeding, 
weight loss, anorexia, new onset or significant worsening of constipation symptoms and a 
family history of colorectal cancer or inflammatory bowel disease.36,37 . The presence of 
alarm symptoms, or if the patient is aged over 50 years, necessitates further investigation, 
using radiological, biochemical, haematological assessment and/or endoscopy. Unfortunately 
however, symptoms of chronic constipation do not reliably predict the subtype of 
constipation, therefore, it is generally necessary to undertake further diagnostic 
investigations.38  
A general examination may aid in identifying a secondary cause of constipation (Table 2). A 
digital rectal examination (DRE) is then recommended to further assess for dyssynergia.  
 
2. Focused Examination to Identify Dyssynergia  
The simplest and most economical clinical tool available for the diagnosis of pelvic floor 
conditions is a digital rectal examination (DRE). The performance of a DRE incorporates an 
assessment for dyssynergia including perineal sensation, ano-cutaneous reflexes, anal resting 
tone and squeeze pressures, abdominal push effort during simulated defaecation with 
associated perineal descent, sphincter and puborectalis relaxation.39 When undertaken by an 
experienced clinician, a DRE has a high sensitivity and positive predictive value for detecting 
dyssynergia as diagnosed by high resolution anal manometry and balloon expulsion test.40 
There is controversy as to whether further testing is required to confirm Rome IV criteria of 
dyssynergic defaecation prior to commencing treatment. However, the poor specificity of 
DRE (58.7%-87%) allows justification for the Rome criteria to recommend the use of 
diagnostic modalities for the formal diagnosis of dyssynergia.40–42 
 
3. Initial Approach 
General measures: 
Given the scope of this review, the fundamental management of patients with dyssynergic 
defaecation, rather than constipation as a whole, is discussed. NHMRC guidelines advise a 
soluble fibre dietary intake of 20g per day in women and 30g in males, this can be 
supplemented using psyllium or sterculia preparations.43 There is insufficient evidence to 
demonstrate that patients with constipation  consume less fibre than those with normal bowel 
habits nor that they will symptomatically improve with an increase in fibre intake.32,44,45  In 
addition, a fluid intake of 2.1L in females and 2.6L in males per day in mild climates has 
been recommended with additional fluid consumption in hotter regions to prevent 
dehydration and difficult to evacuate, hard stools.43 The benefit of exercise in the 
management of chronic constipation has not been supported by the literature.46 It is suggested 
that physical activity may improve quality of life but not symptoms of constipation.47–49  
Pharmacological management: 
Pharmacological management of dyssynergic defaecation includes the avoidance of 
exacerbating medications such as iron and calcium supplements, antacids, opioids, calcium-
channel antagonists, antipsychotics and antispasmodics. Medications that promote the 
passage of stool such as stool softeners (sodium and calcium docusate compounds) and 
osmotic laxatives (preferably polyethylene glycol (PEG) based) are preferred over stimulant 
laxatives.50,51 Suppositories may also be of benefit including the use of a Bisacodyl 
suppository for patients with soft stools or a Glycerol suppository if the patient describes hard 
stools.34  
 
4. Second Line Approach 
In patients who do not respond to conservative treatment measures, further testing and 
management using biofeedback therapy may be initiated. The most important outcome of 
investigations is to predict response to treatment and aid stratification of patients to a specific 
therapy. Frustratingly, there is no gold standard diagnostic modality for diagnosing 
dyssynergic defaecation in patients with chronic constipation. There is also evidence of 
disparity when evaluating between modalities and also with their use in isolation.52 This has 
compromised trial outcomes for the evaluation and management of dyssynergic defaecation. 
Despite this, initial identification of dyssynergia by functional testing using two diagnostic 
modalities including balloon expulsion test, anorectal manometry or electromyography 
(EMG) allows confirmation of the diagnosis using the Rome IV criteria and justifies the 
initiation of biofeedback therapy.7  
 
Balloon Expulsion Test 
The balloon expulsion test is a simple, clinical procedure. A balloon tipped catheter is 
inserted in to the rectum and inflated with water to 50ml. The patient is asked to evacuate the 
balloon while timed. A normal test result is the expulsion of the balloon under one to two 
minutes whereas dyssynergia is suspected if the patient is unable to expel the balloon within 
three minutes.22,53,54 The balloon expulsion test has an 80-90% specificity for dyssynergia but 
is poorly sensitive (50%)10,22,50 There is a high false positive rate if performed in the left 
lateral position and hence it is recommended the patient be in a seated position to accurately 
simulate defaecation.  
 
Anorectal Manometry  
Anorectal manometry indirectly assesses anorectal function by measuring recto-anal 
pressures and motor coordination.52 It evaluates: i) anal sphincter function ii) recto-anal 
reflex activity iii) changes in anal and rectal pressures during simulated defaecation. 
Furthermore the current configuration of catheters allows integrated measurement of rectal 
sensation,  rectal compliance and performance of a balloon expulsion test.54 Findings from 
high resolution anorectal manometry need to be interpreted in context with supporting 
modalities as used in isolation it has limited application in dyssynergia due to high false 
positive values.52,55 
Electromyography  
Electromyography assesses the activity of EAS and puborectalis by detecting paradoxical 
muscular contraction via recording the number of motor units firing at a certain time point. 
Surface EMG is most commonly utilised, where electrodes placed on the anal skin over the 
external anal sphincter is utilized. A sustained increase in surface EMG activity (>50% 
increase from baseline) on attempted defaecation is defined as inappropriate contraction.19,11 
EMG has been shown to correlate with balloon expulsion in 82% of patients.56,57 
Following confirmation of dyssynergia on diagnostic testing using two modalities, further 
management using a behavioural therapy such as biofeedback therapy can be commenced. 
   
Biofeedback  
Definition of Biofeedback  
Biofeedback is a behavioural therapy which incorporates exercise repetition and simulation 
of defaecation to safely coordinate abdominal and pelvic floor muscle contraction.10 It is a 
form of operant (Skinnerian) conditioning utilising consequences as a means of modifying 
the occurrence or type of behaviour. All patients with confirmed dyssynergic defaecation 
should be considered for biofeedback therapy.26,58 Biofeedback therapy is optimally 
combined with a holistic behavioural and general pharmacological treatment plan tailored to 
the individual patient. It includes the use of objective measures of function including EMG, 
anorectal manometry, ultrasound or digital palpation to “feedback” to the patient what is 
normal or abnormal with the aim to modify patterns of defaecation. Exercises are repeated 
and corrected until the patient can perform the correct action independently.This can be 
coupled with habit training about toileting patterns and psycho-social aspects of toilet use. 
 
Procedure, duration and frequency of training 
Fundamental to all behavioural therapies including that of biofeedback therapy is the 
instruction and training by the therapist who corrects and improves muscle control which 
translates into actual function. Biofeedback therapy is ideally undertaken in the correct 
defaecation position (seated, leaning forward at 45 degree angle, legs apart) with the 
biofeedback instrument in situ.32 The key components of a biofeedback session includes 
instruction on: i) diaphragmatic breathing ii) increase in intraabdominal pressure associated 
with push effort iii) coordinated pelvic floor relaxation iv) simulated defaecation and may 
also incorporate v) rectal sensory retraining in patients with altered visceral sensitivity.10,32 
Biofeedback protocols vary between specialist centers and require instruction by an 
experienced practitioner (physician, physiotherapist or nurse). A proposed protocol is 
demonstrated in Figure 5.  Biofeedback training optimally requires 5-6 training sessions on a 
fortnightly basis, each lasting 30-60 minutes but should be individualised based on patient 
requirements.59 Contraindications to biofeedback therapy include; pregnancy, active infection 
or inflammation, active fissures or acute postoperative period.  
 
Mechanism of action 
Dyssynergic defaecation is primarily an acquired condition, therefore, the aim of biofeedback 
is to relearn a normal pattern of defaecation.32 The mechanism by which biofeedback 
improves constipation symptoms and bowel function remains incompletely understood. 
Studies suggest that biofeedback acts locally and improves constipation by removing the 
mechanical barrier (acute anorectal angle) caused by paradoxical pelvic floor contraction. 
Relaxation of the pelvic floor muscles allow stool to be propelled forward more readily and 
may eliminate retrograde peristalsis caused by pelvic floor contraction during 
defaecation.19,60,61 There is also data that suggests biofeedback may play a role in 
neuromodulation of the gut.19 Patients with constipation have a reduced rectal mucosal blood 
flow which reflects the activity of extrinsic autonomic innervation to the gut.19,62 This is seen 
most obviously in patients with slow transit constipation.19 It has been demonstrated that such 
patients, with a positive response to biofeedback therapy, have enhanced gut microcirculation 
resulting in a decreased stool transit time.19 The improvement in gut blood flow is due to 
increased cholinergic and decreased sympathetic inhibition, suggesting biofeedback may 
modify autonomic pathways. 
 
Instrument modalities 
Instruments used for biofeedback may include a solid state manometry system, 
electromyography (EMG), rectal balloon, ultrasound (intrarectal, intravaginal, perineal), 
digital guidance or visual feedback techniques.63–65  
The solid state manometry system includes a probe with microtransducers embedded in it 
which is connected to a display unit for interpretation of pressure activity and a balloon for 
simulated defaecation and sensory training.  EMG biofeedback systems commonly include a 
surface electrode attached to a probe or a sensor placed on the surface of the external anal 
sphincter which is connected to a display unit and provides real time visual and auditory 
feedback.  
Balloon biofeedback may also be undertaken with the patient in the left lateral position or 
seated on a commode. A catheter with a balloon attached is inserted 10cm into the rectum. 
Fifty millilitres (mL) of water or air is injected into the balloon to provide sensory awareness, 
the patient is instructed to generate increased intraabdominal pressure using the diaphragm 
and abdominal muscles while simultaneously relaxing the pelvic floor and anal sphincter 
muscles to release the balloon without straining. The therapist holds the end of the balloon 
catheter to assess balloon movement (propulsion) and may apply gentle traction to the 
balloon catheter to assist initially.  
If the patient is unable to evacuate a 50ml balloon then water or air can be sequentially 
removed until the patient is able to expel the balloon.66 In patients with altered rectal 
sensitivity, balloon biofeedback can be undertaken by serially inflating a balloon with 
incrementally smaller or larger volumes; enabling the patient to appreciate rectal filling and 
to attempt evacuation at an appropriate threshold. 
The use of ultrasound imaging for the purpose of biofeedback is a new concept which 
provides real time information about the direction of pelvic floor movement during pelvic 
floor muscle contraction and relaxation to assist teaching a patient to relax the muscles during 
defaecation.  
Head-to-head trials between biofeedback treatment techniques are limited and significant 
disparity between treatment protocols comparing different techniques makes it challenging to 
identify the most efficacious technique (Table 3).25 Koh et al., undertook a meta-analysis 
comparing EMG biofeedback with non-EMG biofeedback and found a OR of 6.738 (95% CI, 
2.914 to 15.580, p<0.001) favouring EMG.25 A recent Cochrane Review also found that there 
was a lack of evidence to make a clear conclusion of the most efficacious modality.67 EMG 
biofeedback demonstrated a slightly superior response compared with balloon biofeedback 
and manometry, however, the findings were not statistically significant.67 
 
Efficacy of biofeedback in dyssynergic defaecation 
Biofeedback for dyssynergic defaecation has response rates of up to 80% improvement in 
symptoms with sustained results at 24 months.68,69 Ten randomised controlled trials 
comparing biofeedback with other medical management and numerous uncontrolled trials 
have formed the foundation for the integration of biofeedback into clinical practice in patients 
who have failed conservative medical therapy, detailed in Table 4.  
Of note are the following landmark studies. Chiarioni et al., randomised 104 patients with 
dyssynergia to PEG laxatives or EMG biofeedback and assessed their response at 6 and 12 
months.69 Eighty percent of patients who underwent biofeedback reported a major 
improvement in symptoms compared with 22% of patients in the laxative treated group 
(p<0.01); the benefit of biofeedback was sustained at 24 months.69  Rao et al., compared anal 
pressure biofeedback against two control conditions; sham biofeedback and standard care.68 
Standard care subjects received diet and lifestyle advice, laxatives and scheduled evacuations. 
At 3 months follow up 79% of patients in the biofeedback group corrected dyssynergia 
(p<0.0001) compared with 4% receiving sham and 8.3% receiving standard treatment.68 
Increased complete spontaneous bowel movements and higher global bowel satisfaction was 
also demonstrated in the biofeedback group compared with sham. 68 Heymen et al., compared 
two control conditions, placebo or diazepam against EMG biofeedback.21 The trial involved 3 
phases including a run in which involved enhanced standard care including diet, lifestyle 
measures, stool softeners and scheduled evacuations. Of the 117 patients who commenced 
the trial, 18 reported adequate relief at the end of run in and were excluded.21  The remaining 
84 patients were randomised to placebo, diazepam and biofeedback. At the 3 month follow 
up 70% of the biofeedback group reported adequate relief compared with 30% of the 
diazepam treated (p<0.001) and 38% of placebo treated patients (p=0.017).21 A meta-analysis 
by Koh et al., demonstrated the overall effectiveness of biofeedback with an OR of 5.861 
(95% CI, 2.175 to 15.794, p<0.001) in favour of biofeedback compared with non-
biofeedback treatment.25  
 
Biofeedback is practitioner dependent and often individualised to a particular patient’s needs. 
This variability makes intra- and inter-centre comparisons challenging and leads to inherent 
difficulties in designing and interpreting studies. This difficulty was recognised in a recent 
Cochrane Review which concluded that the efficacy and safety of biofeedback could not be 
determined due to inadequacies in study methodology and bias.67 Seventeen studies were 
included in the Cochrane review comprising of a total of 931 participants. Standard medical 
management was not systematically established between studies. Due to the heterogeneity 
between study populations, samples, technique methods and outcome measures a meta-
analysis was not able to be undertaken. Despite the finding from the Cochrane Review, the 
randomized controlled trials in Table 4 demonstrate compelling evidence for the utilization of 
biofeedback therapy for patients with dyssynergic defaecation.  
 
Efficacy of biofeedback in slow transit constipation 
Studies of biofeedback therapy in patients with slow transit constipation and dyssynergia 
have demonstrated a beneficial response rate of 50%.70,71 It has been postulated that patients 
with rectal evacuatory dysfunction and slow transit may have secondary colonic dysmotility 
as improvement in dyssynergia is associated with improvement with colonic transit.72 
However, evacuatory dysfunction is not associated with an identifiable specific pattern of 
transit delay.73  
Contention also remains as to whether biofeedback improves whole gut transit in slow transit 
constipation without dyssynergia.19,70 In their prospective study, Emmanuel and Kamm 
demonstrated that gut directed biofeedback is an effective behavioural treatment for chronic 
idiopathic constipation, with 59% of patients reporting subjective improvement.19 In addition, 
59% of patients with slow transit constipation normalized their transit time at the end of 
treatment.19 There was also evidence of improving transit time in patients with normal 
transit.19  In this study, it was also found that patients with constipation, most obviously in 
those with slow transit, had abnormal cardiovagal cholinergic test scores and reduced rectal 
blood flow, markers of autonomic function. In patients who demonstrated improvement with 
biofeedback there was an increase in rectal mucosal blood flow with no variation of abnormal 
cardiovascular autonomic reflexes. This suggests that biofeedback results in a gut specific 
mechanism of action mediated centrally. 
 In contrast, Chiarioni et al., in their study of 52 patients demonstrated that 71% of patients 
with combined slow transit constipation and pelvic floor dyssynergia improved following 
biofeedback training compared with 8% in the slow transit only group.70 This study 
suggested that biofeedback resource allocation  should be directed at those patients with 
pelvic floor dyssynergia with or without coexisting slow transit.70 Further research is 
warranted to determine those likely to benefit most from biofeedback. 
Clinical predictors of success 
Biofeedback is a labour intensive therapy predominantly performed in specialised tertiary 
centers which limits patient access.74 The majority of biofeedback studies specifically selected 
patients with a functional defaecation disorder although a smaller number of studies have 
shown possible benefit in all patients with constipation.19,75 Clinical predictors of success for 
biofeedback therapy may aid in resource allocation. Clinical predictors that have demonstrated 
an increased likelihood of beneficial effect include: harder stool consistency, shorter duration 
of laxative use and willingness to comply with treatment protocols.74 Physiological parameters 
on anorectal manometry that correlate with clinical improvement with biofeedback are a high 
straining rectal pressure and a prolonged balloon expulsion time.74 Risk factors for a poor 
response to biofeedback include a long history of constipation, an eating disorder or poor 
compliance. Manometric findings of anal canal hypertonia, a long anal canal, increased rectal 
maximum tolerable volume, poor pre-treatment defaecation index and paradoxical contraction 
specifically in those patients with severe defaecatory dysfunction due to anatomical or 
physiological impairment may also predict a poor response.76,77,78,79 However, despite negative 
predictors patients may have a reasonable response to therapy.80 Symptom improvement in 
patients with good compliance can be demonstrated within one to six months.  
To date the vast majority of biofeedback trials have only included patients diagnosed with a 
functional defaecation disorder by anorectal manometry or balloon expulsion. Hence, it 
seems reasonable to use similar criteria to select patient for biofeedback therapy. 
Symptomatic improvement is also known to correlate with correction of anorectal 
manometric abnormalities and at least one trial has shown poor response of biofeedback in 
patients without dyssynergic defaecation.70 There remains significant controversy as to the 
clinical utility of tests of anorectal function and the role of biofeedback in patients without 
dyssynergic defaecation as there is evidence that there may be a role for a behavioural 
therapy such as biofeedback therapy in all constipated patients.19,75 
5. Specialist Testing 
Defaecating proctography  
Defaecating proctography involves the insertion of barium paste into the rectum followed by 
videofluoroscopy at rest and during rectal evacuation.10,81,82 Defaecating proctography is a 
cost-effective procedure which mimics normal defaecation. A lack of perineal descent and an 
evacuation time longer than 30 seconds is highly predictive of dyssynergia.83,84 
Unfortunately, defaecating proctography is often poorly tolerated, can be difficult to access 
outside of tertiary centers and involves exposure to low-dose ionising radiation (average dose 
4.9 mSv).85 
 
Magnetic Resonance Imaging (MRI) 
MRI is a highly validated modality with negligible radiation which allows a global 
assessment of pelvic floor muscles (in particular of sphincter defects) and their function. 
Interestingly, it has a diagnostic sensitivity of 70% compared to that of defecating 
proctography despite improved image resolution.81 Unfortunately, it is expensive and there 
are few functional MRI facilities, in particular those with an open magnet enabling patients to 
be seated during the evacuation phase. 
  
Ultrasound 
Ultrasound is a portable and inexpensive imaging modality which avoids radiation and is 
effective in assessing both anatomy and function of the pelvic floor. Two-dimensional (2D) 
and three-dimensional (3D) ultrasound is readily available and emerging techniques using 
four-dimensional (4D) including echo defaecography and endoanal ultrasound technology is 
available in selected centers. Echo defecography (3D dynamic anorectal US) is utilised at few 
centers and has been shown to correlate well with defecography and was validated in a 
prospective multicentre study. 86,87 Overall, ultrasound is a well-tolerated, reliable modality 
but is operator dependant and has a limited field of view.  
 
Colonic transit studies 
There is an apparent relationship between colonic transit and evacuatory outlet obstruction 
caused by dyssynergia, whereby evacuation impairment may result in slowed transit.88 If 
there is a suspicion of slow transit constipation or overlap with pelvic floor dyssynergia a 
colonic transit study may be requested to assess whole gut transit as there are discernible 
treatment implications.  
Radio –opaque marker study 
The most accessible investigation is a radio-opaque marker (Sitzmark or Kolomark) study. 
The patient consumes a capsule containing radio-opaque markers and subsequent abdominal 
radiographs are taken to assess the progression of markers through the colon. Colonic transit 
studies separate results into normal or slow transit times based on the number of markers 
retained on x-ray after ingestion. It is a simple, reliable and reproducible test. However, it 
exposes patients to radiation and does not measure the transit of a physiological meal.89  
Scintigraphic studies  
Scintigraphic studies measure total gut transit and regional colonic transit via the ingestion of 
a radiolabelled meal (for gastric and small bowel transit) or coated capsule with radiopaque 
markers dispersed in the ileocaecal region.90 Scintigraphy provides accurate information 
about transit through individual colonic regions, however, it exposes the patient to 
radiation.91 
Wireless Motility Capsule 
Wireless motility capsule is an emerging imaging modality that can identify normal, slow and 
rapid colonic transit time without radiation. There are a number of contraindications to its use 
including swallowing difficulties, however it is generally well tolerated. It is expensive and 
has a retention rate of 0.33%.92  
 
6.       Additional management  
Botulinum toxin injection 
Botulinum toxin injection into non-relaxing puborectalis has shown temporary improvement 
in patients with dyssynergic defaecation but is not widely utilised.93,94,95 Based on small 
uncontrolled studies, Botulinum toxin has demonstrated an inconsistent improvement in 
symptoms and its effect decreases within three months post injection. A recent AGA 
technical review on constipation has noted that Botulinum toxin injection is not superior to 
biofeedback as first line therapy in patients with dyssynergic defaecation.26,59,96 
 
 
Surgery 
In patients without dyssynergia or in refractory cases of dyssynergic defaecation, surgery 
should be considered only if there is a significant effect on quality of life and after 
nonsurgical measures have failed. Partial surgical division of the puborectalis muscle has 
demonstrated to be effective, however, it has an unacceptable risk of faecal incontinence and 
overall poor results.97 A number of studies have demonstrated that the stapled transanal rectal 
resection (STARR) procedure to be superior to behavioural therapy using biofeedback, 
however, the outcomes of biofeedback demonstrated in these surgical studies were strikingly 
poor and the complications (pelvic sepsis, fistula, peritonitis, bowel perforation, pain, and 
bleeding) in addition to long term results were suboptimal. 98,99, 100 Given this, surgery is no 
longer recommended for the management of dyssynergic defaecation. 
 
7.          Further areas of interest 
The management of pelvic floor dyssynergia has also been investigated in patients with 
inflammatory bowel disease.101 It has been found that a significant number of these patients 
with evacuatory dysfunction have concomitant pelvic floor dyssynergia. Biofeedback therapy 
in this cohort has demonstrated encouraging results with 80% reporting improvement in 
symptoms.102  
Biofeedback has also been utilised in patients with spinal cord and neurogenic bowel 
dysfunction. A recent study by Mazor et al., demonstrated that patients with incomplete 
motor spinal cord injury responded as well as matched controls to anorectal biofeedback.103 
Improvement in anorectal sensorimotor function and balloon expulsion was also 
demonstrated in these patients.103 Biofeedback has also been used with success in patients 
with multiple sclerosis who have constipation.104 
For practical purposes, home biofeedback may enable patients in rural or regional settings to 
access this treatment. Home based training devices predominantly use an EMG home trainer 
or silicone probe device where pressure or electrical activity can be simply displayed. The 
few studies that have examined home biofeedback have demonstrated encouraging results.105  
 
Despite an increase in evidence based research into pelvic floor dyssynergia in chronic 
constipation and its management, there are a number of areas which require further research. 
Biofeedback modality head-to-head trials need to be undertaken to determine a gold standard 
diagnostic modality. Studies evaluating the economic benefit and impact of biofeedback 
therapy on reducing primary care visits may allow an increase in funding to this treatment 
technique. Further studies exploring new biofeedback techniques and home biofeedback 
would be beneficial. 
 
Conclusion 
Chronic constipation is a common clinical presentation that adversely affects quality of life 
for many patients. Dyssynergic defaecation is an under-recognised, potentially reversible 
cause for chronic constipation. There is no gold standard diagnostic modality for dyssynergic 
defaecation and further research is required in this area. In patients diagnosed with a 
functional defaecation disorder, biofeedback therapy is the most efficacious treatment 
available. There is also emerging evidence that biofeedback may be beneficial in other 
conditions (i.e. slow transit constipation, irritable bowel syndrome or inflammatory bowel 
disease). Further research into biofeedback therapy with standardised protocols and patient 
centered outcomes is required to expand its utility in clinical practice.  
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 Table 1: Rome IV Criteria for Functional Constipation, Functional Defaecation 
disorder including Dyssynergic Defaecation 
Functional Constipation6 
Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to 
diagnosis 
1. Must include 2 or more of the following 
a. Straining during more than one-fourth (25%) of defaecations 
b. Lumpy or hard stools (BSFS 1-2) more than one-fourth (25%) of defaecations 
c. Sensation of incomplete evacuation more than one-fourth (25%) of defaecations 
d. Sensation of anorectal obstruction/blockage more than one-fourth (25%) of 
defaecations 
e. Manual maneuvers to facilitate more than one-fourth (25%) of defaecations (eg. 
Digital evacuation, support of the pelvic floor) 
f. Fewer than 3 spontaneous bowel movements per week 
 
Functional Defaecation Disorder7 
Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis 
 1. The patient must satisfy diagnostic criteria for functional 
constipation and/or irritable bowel syndrome with constipation 
2. During repeated attempts to defecate, there must be features of 
impaired evacuation as demonstrated by 2 of the following 3 tests: 
a) Abnormal balloon expulsion test 
b) Abnormal anorectal evacuation pattern with manometry or anal 
surface EMG 
c) Impaired rectal evacuation by imaging 
 
Dyssynergic Defaecation7 
Inappropriate contraction of the pelvic floor as measured with anal 
surface EMG or manometry with adequate propulsive forces during 
attempted defaecation  
 
Table 2: Causes of Chronic Constipation 
Constipation Causes 
Primary  1. normal transit 
2. slow transit 
3. evacuation disorder:  
(i) structural (rectocoele, enterocoele) 
(ii) functional (Dyssynergic defaecation, IBS-C, slow transit 
constipation with dyssynergia) 
Secondary  8. Medications (narcotics) 
9. Metabolic (hypothyroidism, hypercalcemia) 
10. Neurologic disorders (Parkinson’s disease, multiple 
sclerosis) 
11. Obstructing colorectal cancers 
12. Systemic (scleroderma, amyloidosis) 
13. Psychiatric (depression) 
 
 
Table 3: Comparison between biofeedback modalities 
Study 
authors 
Study 
publication 
year 
Study details Primary 
outcome 
Overall result Limitation/ 
Bias 
Bleijenberg 
and 
Kuijpers106 
1994 RCT  
11patients: EMG 
biofeedback 
9 patients: 
balloon 
biofeedback 
Standard 
EMG, 
constipation 
score, 
standard 
diary 
Change score 
significant 
improvement with 
EMG (8/11) vs. 
balloon (2/9) 
Blinding 
Koutsomanis 
et al.107 
1995 RCT  
60 patients 
unresponsive to 
standard 
treatment 
n=47: pelvic 
floor dyssynergia 
n=17 slow 
transit. 
Visual 
biofeedback vs 
muscle training 
no visual display 
2-3 month follow 
up 
Patient 
symptom 
diary, whole 
gut transit, 
surface 
EMG, 
simulated 
defaecation.  
14/31 visual 
biofeedback 
improved 
symptoms vs 12 of 
28 in muscle 
training group, 
changes in bowel 
frequency, 
duration of 
abdominal pain 
and improvement 
in anismus index 
were similar in 
both groups   
Blinding 
Glia et al.108 1997 RCT 
26 patients 
n=10:anal 
manometry, 
n=10:EMG 
6 month 
followup 
Balloon 
expulsion 
test, anorectal 
manometry 
and EMG, 
bowel 
symptom 
diary, global 
rating of 
treatment 
15/26 (58%) 
patients improved 
anorectal function 
and symptoms. Of 
those that 
completed therapy 
15/20 
(75%)improved 
symptom with 
persistence at 6 
month follow up. 
No difference in 
Blinding, attrition 
bias 
Low power 
efficacy of 
feedback modes.  
Pourmomeny 
et al.109  
2010 RCT 
Follow up 1week 
post treatment 
65 patients n=34 
EMG 
biofeedback, 
n=31 balloon 
assisted training  
Satisfaction 
(low, 
moderate, 
high), change 
in Rome 
criteria, 
ability to 
expel a 
balloon 
Reduction in 
constipation in 
both groups, 
improved balloon 
evacuation, patient 
satisfaction 52% in 
balloon training 
and 79% in 
biofeedback.  
Selection, 
blinding, 
reporting bias 
 
 
Table 4: Comparison between Randomised Controlled Trials of Biofeedback vs.Non-
Biofeedback modalities 
 Chang et al.110 Chiarioni et al. 69 Rao et al.68 Heymen et al.21    Rao et al.111       
Study publication 
year 
2003 2006 2007 2007 2010 
Study design RCT 
Electrical 
stimulation therapy 
(EST) versus EMG 
biofeedback 
RCT 
Biofeedback versus 
polyethylene glycol 
(PEG) 14.6g 
RCT 
Biofeedback versus 
sham versus sham 
biofeedback 
RCT 
Biofeedback 
versus diazepam 
versus placebo  
RCT 
Biofeedback  versus 
conventional medical therapy 
Followed up for 12 months 
Detail Electrical 
stimulation using 
anal plug versus 
EMG biofeedback 
with visual display. 
Total study duration 
10-12 days.  
Patients with chronic 
severe PFD were 
treated with fibre plus 
enemas or 
suppositories up to 
twice weekly. 
Nonresponders were 
randomised to 
biofeedback or PEG 
plus counselling 
sessions. 
Anal pressure 
biofeedback  
compared to two 
control conditions, 
sham biofeedback 
and standard care.  
Standard: diet and 
lifestyle advice, 
laxatives and 
scheduled 
evacuations versus 
Biofeedback versus 
Sham biofeedback 
RCT involving 3 
phase run in, 
treatment, follow 
up. Patients were 
assigned to 
biofeedback, 
diazepam or 
placebo. 
Partially blinded 
trial.  
RCT involving short term 
therapy followed by those 
who completed biofeedback 
therapy were asked to 
continue for long term study 
Subjects 22 total 
12 electrical 
stimulation 
10 EMG 
biofeedback 
104 total 
55 PEG plus 
counselling 
54 biofeedback 
77 total 
24 standard therapy 
28 biofeedback 
25 sham 
biofeedback 
 
84 total 
24 placebo 
30 diazepam 
30 biofeedback 
52 total randomized 
44 completed 
short term therapy 
13 completed long term study 
with biofeedback 
Type of biofeedback 
and duration  
10-14 sessions 
lasting 60-90 
minutes 
EMG biofeedback 
with visual display 
5 x weekly 30min 
training sessions 
Intraanal EMG probe 
Balloon defaecation 
test 
2 x per week 1 hour 
biofeedback session. 
Up to 6 sessions 
within 3 months.  
Anal pressure 
biofeedback using 
manometry probe  
2 x per week 50 
min session 
6 sessions within 
3 months 
EMG with anal 
plug 
Short term phase: 2x per 
week 1 hour biofeedback. Up 
to 6 sessions within 3 
months. Long term study: 3 
follow up visits at 3 monthly 
intervals. Last review at 12 
months.   
Intraanal manometric probe.  
 Primary outcomes Symptom 
questionnaire, 
anorectal 
manometry before 
and after, balloon 
distension 
Global Improvement 
of Symptoms 
Physiological 
variables: change in 
anal canal pressure, 
pelvic floor EMG 
when straining and 
balloon expulsion 
4. Presence of 
dyssynergia 
5. Balloon expulsion 
time 
6. Number of complete 
spontaneous 
bowel 
movements 
7. Global satisfaction 
Global symptom 
relief 
Primary outcome: number of 
complete spontaneous bowel 
movements (CSBM)/week. 
Secondary outcomes: global 
bowel satisfaction, stool 
frequency, stool consistency, 
straining effort, digital 
assistance and laxative 
consumption score per week.  
 
Response rates 
 
Global improvement 
in symptoms in both 
groups (48.3% 
bowel satisfaction in 
electrical 
stimulation group 
and 59% in 
biofeedback 
patients)  
 
80% major 
improvement at 6 
months in biofeedback 
group. Laxative 
treated had 22% 
improvement in 
symptoms.  
Biofeedback benefit 
sustained at 24 
months.  
 
Dyssynergia 
correction at 3 
months: 
Biofeedback- 79% 
Sham- 4% 
Standard 6% 
At 3 months follow 
up the biofeedback 
group reported more 
complete 
spontaneous bowel 
movements, 
defaecation 
improvement and 
higher satisfaction 
than the sham 
treated group. 
 
 
Improved 
symptoms: 
Biofeedback- 
70% 
Diazepam – 30% 
Placebo- 38% 
Sustained improvement in 
results at 12 months.  
Significant increased 
CSBM/week (p=<0.001), 
significant improvement in 
normalisation of dyssynergic 
muscle pattern (p=<0.0010). 
significant improvement in 
normalisation of colonic 
transit (p<0.01) and 
improvement in balloon 
expulsion (p<001) 
 
Overall result 
 
 
 
 
EST comparable to 
biofeedback therapy 
in patients with 
impaired rectal 
sensation. EST can 
be considered as an 
adjunctive 
therapeutic modality 
EST  
 
 
 
 
 
Biofeedback superior 
to laxatives 
 
 
 
 
 
 
 
 
Biofeedback was 
superior to standard 
therapy and sham 
biofeedback 
 
 
Biofeedback is 
superior to 
diazepam and 
placebo 
 
 
 
Sustained response to 
biofeedback therapy. 
Biofeedback is superior to 
conventional medical therapy 
 
 
Limitations/ Bias  Performance and 
detection bias 
Performance and 
detection bias 
 
Performance and 
detection bias 
 
Performance and 
detection bias 
 
Performance and detection 
bias 
 
 Jung et al.112  
(abstract only) 
Simon and 
Bueno113 
Hart et al.114 Ba-bai-ke-re et al.115 Cadeddu et al.116 
Study publication year 2007 2009 2012 2014 2015 
 
Study design 
 
RCT 
 
RCT 
Follow up for 2 
months post-
treatment 
 
RCT 
12 weeks duration 
with no follow up 
 
RCT 
Follow up 1, 3, 6 
months post treatment 
 
 
RCT 
Follow up at 6 
months 
post treatment 
Detail Randomised cross-
over design 5 week 
duration. Electrical 
stimulation therapy 
(EST) for 2 weeks 
then biofeedback for 
5 weeks versus 
biofeedback for 5 
weeks then EST for 
2 weeks 
EMG biofeedback  
vs. 8 counselling 
sessions with EMG 
assessment during 
straining to defecate  
in chronically 
constipated elderly 
patients 
EMG (rectal probe) 
biofeedback plus 
coaching for pelvic 
floor relaxation vs. 
muscle relaxation 
techniques, emg with 
sham surface 
electrode placement 
Anorectal manometry 
vs. Polyethylene 
glycol (PEG) 17g, 3 
times daily with high 
fibre diet.  
Intra-anal EMG 
biofeedback plus  
electrical 
stimulation vs. 
standard care 
(counselling, fibre 
diet, lifestyle,  
enemas) 
Subjects   40 patients with 
pelvic floor 
dyssynergia n=20: 
electrical 
stimulation, n=20: 
biofeedback therapy 
30 patients with 
dyssynergic 
defaecation 
n=15 EMG 
biofeedback 
n=15 Control 
21 patients with 
pelvic floor 
dyssynergia, failed 
lifestyle modification 
and other medical 
intervention. n=10  
biofeedback, n=11 
control 
88 patients confirmed 
dyssynergic 
defaecation 
n= 44 anorectal 
manometry 
biofeedback, n=44 
oral PEG 
81 patients 
n=40 intra-anal 
EMG biofeedback  
plus transanal 
electrostimulation,  
n=41 control 
patients  
 
Type of biofeedback and 
duration  
Unspecified 
modality 
EMG biofeedback, 8 
sessions over 1 
month with visual 
and auditory 
feedback  
EMG biofeedback 
6x1hour sessions plus 
home practice 
Anorectal manometry 
30mins x5 weeks, 
home practice 
encouraged 
6x 20 minute 
weekly sessions 
Intra-anal EMG 
biofeedback and 
6x20 minute  
transanal 
stimulation   
 
Primary outcomes 
 
Symptom 
assessment, patients 
opinion, anorectal 
manometry, balloon 
expulsion, substance 
P expression within 
rectal mucosa 
 
Self reported bowel 
frequency, sensation 
of incomplete 
evacuation, 
evacuation difficulty 
and perianal pain on 
defaecation, Latter 3 
symptoms rated on a 
scale, EMG activity 
and anismus index 
  
Constipation severity 
instrument, irritable 
bowel quality of life 
scale, SF-36, trauma 
history questionnaire 
 
Constipation 
symptoms, Wexner 
score, Quality of life 
score 
 
PAC-QOL, 
anorectal 
manometry and 
balloon expulsion 
test at baseline, 
Wexner score and 
obstructed 
defaecation score  
end of treatment 
and 6 months after 
treatment 
 
 
 
 
 
 
Response rates 
 
Overall satisfaction 
improved 
significantly in both 
groups, after 2nd 
treatment the 
success was 80% in 
both groups. 
Objective 
parameters such as 
resting anal 
sphincter pressure 
decreased in 
biofeedback 
predominant group. 
 
Significant 
difference (p<0.01) 
in frequency of 
defaecations, 
sensation of 
incomplete 
evacuation, perianal 
pain, difficulty of 
evacuation, EMG 
activity during 
straining and 
anismus index in 
EMG biofeedback 
group only. 
Significant 
difference 
 
Biofeedback group 
constipation scores 
decreased by 35.5% 
comared with 15.3% 
in control and 
obstructive 
defaecation symptom 
scores decreased by 
37.9% compared with 
19.7%. Improvement 
in IBS-QOL. SF-36 
improved 28% 
compared with 
control which 
worsened 12.7% 
 
After completing the 
course of biofeedback 
treatment 
improvement in 
clinical symptoms and 
Wexner Constipation 
Score were decreased 
compared with oral 
PEG group (p<0.05).  
Significant 
improvement at 6 
months in difficult 
evacuation, perianal 
pain, hard stools, 
laxative dependence, 
Wexner Constipation 
  
Significant 
decrease in 
Wexner score and 
obstructed 
defaecation score 
(p<0.0102, 
p<0.0001 
respectively). No 
significant change 
in control group. 
PAC-QOL 
improved 
significantly 
(p<0.0001) in 
EMG biofeedback 
group otherwise 
  
 
Figure 2: Levator Ani musculature 
 
(p<0.01)between 
initial assessment 
and treatment but 
not between 
treatment and follow 
up(p>0.05) 
score and Quality of 
life score (p<0.05) 
PAC-QOL did not 
change in control 
group.  
 
Overall result 
 
 
 
 
 
 
EST efficacy 
comparable to 
biofeedback. EST 
has a beneficial 
effect in addition to 
biofeedback 
therapy.  
 
EMG biofeedback 
superior to control. 
Benefits maintained 
at 2 months post.  
 
 
 
 
 
  
Biofeedback superior  
to control 
 
 
 
 
 
Manometric 
biofeedback superior 
to oral PEG with 
sustained response at 
6 months 
 
 
Biofeedback plus 
transanal 
electrostimulation 
provided 
sustained 
improvement. 
Standard therapy 
was large 
ineffective.  
 
 
Limitations/Bias Abstract only  Blinding Under powered, 
blinding, attrition bias 
Blinding Blinding 
 Figure 3: Comparison of the anorectal angle during puborectalis contraction and 
relaxation.  
 
A. Contracted
B. Relaxed
 KEY POINTS  
 Dyssynergic defaecation attributes to 50% of patients with 
chronic constipation who don’t respond to standard 
medical therapy 
 Diagnosis starts with history (straining, incomplete 
evacuation), DRE to assess for paradoxical contraction of 
puborectalis. Balloon expulsion, anorectal manometry or 
surface EMG can confirm. 
 Biofeedback therapy is first line management (up to 70% 
of patients demonstrate improved symptoms) for 
dyssynergic defecation 
 
 
 
